Home Newsfeeds Baird Maintains Neutral on Autoliv, Raises Price Target to $81

Baird Maintains Neutral on Autoliv, Raises Price Target to $81

Baird analyst Luke Junk maintains Autoliv (NYSE:ALV) with a Neutral and raises the price target from $77 to $81.

byBenzinga Newsdesk

October 24, 2022

1 minute read

Baird analyst Luke Junk maintains Autoliv (NYSE:ALV) with a Neutral and raises the price target from $77 to $81.

Amazon’s Ad Strategy For The Win – BofA Analyst Expects Margin Surge in 2024

By Anusuya Lahiri

January 3, 3:51 PM

Advertising checks for ad spending on Amazon.Com Inc (NASDAQ: AMZN) remain strong (Skai 4Q marketplace ad spending increased 48% Y/Y through Nov), BofA analyst Justin Post writes.

AMZN

FDA
News

Apyx Medical Corporation Announces Results Of The U.S. Ide Clinical Study Evaluating The Use Of Renuvion To Improve The Appearance Of Lax Skin In The Neck And Submental Region; Says Primary Effectiveness Endpoint Of Study Was Met

By Benzinga Newsdesk

July 8, 3:54 PM

Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that the results of

APYX